Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 3
1994 1
1997 1
1998 2
2001 2
2002 4
2004 2
2005 2
2006 3
2007 1
2008 3
2009 3
2010 3
2011 6
2012 10
2013 7
2014 3
2015 5
2016 5
2017 3
2018 4
2020 6
2021 11
2022 11
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. Among authors: burgers ja. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J, Gupta RG, Grootendorst DJ, Eccles LJ, Brahmer JR. Reck M, et al. Among authors: burgers ja. J Thorac Oncol. 2023 Aug;18(8):1055-1069. doi: 10.1016/j.jtho.2023.04.021. Epub 2023 May 3. J Thorac Oncol. 2023. PMID: 37146754 Free article. Clinical Trial.
Endobronchial ultrasound.
Burgers JA, Herth F, Becker HD. Burgers JA, et al. Lung Cancer. 2001 Dec;34 Suppl 2:S109-13. doi: 10.1016/s0169-5002(01)00349-x. Lung Cancer. 2001. PMID: 11720750 Review.
Current chemotherapy strategies in malignant pleural mesothelioma.
de Gooijer CJ, Baas P, Burgers JA. de Gooijer CJ, et al. Among authors: burgers ja. Transl Lung Cancer Res. 2018 Oct;7(5):574-583. doi: 10.21037/tlcr.2018.04.10. Transl Lung Cancer Res. 2018. PMID: 30450296 Free PMC article. Review.
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Douma LH, et al. Among authors: burgers ja. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844598 Clinical Trial.
Tumour Treating Fields for mesothelioma.
de Gooijer CJ, Burgers JA. de Gooijer CJ, et al. Among authors: burgers ja. Lancet Oncol. 2020 Jan;21(1):e9. doi: 10.1016/S1470-2045(19)30828-9. Lancet Oncol. 2020. PMID: 31908313 No abstract available.
Rebuttal From Dr Li et al.
Li WW, Burgers JA, Klomp HM, Hartemink KJ. Li WW, et al. Among authors: burgers ja. Chest. 2015 Dec;148(6):1380-1381. doi: 10.1378/chest.15-1197. Chest. 2015. PMID: 26110719 No abstract available.
Hyperhydration with cisplatin does not influence pemetrexed exposure.
de Rouw N, Derijks HJ, Hilbrands LB, Boosman RJ, Piet B, Koolen SLW, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Aerts JGJV, Croes S, Mathijssen RHJ, Huitema ADR, Burger DM, Biesma B, Ter Heine R. de Rouw N, et al. Among authors: burgers ja. Br J Clin Pharmacol. 2022 Feb;88(2):871-876. doi: 10.1111/bcp.15031. Epub 2021 Aug 26. Br J Clin Pharmacol. 2022. PMID: 34374116 Free PMC article.
96 results